Ionis Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ionis Pharmaceuticals, Inc.
Experts see allogeneic CAR-Ts as less likely to carry potential risks of T-cell malignancies, and an opportunity for differentiation against the crowded autologous CD19-directed CAR-T space.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
- Drug Delivery
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Akcea Therapeutics, Inc.
- Regulus Therapeutics, Inc.
- Symphony GenIsis, Inc.
- Isis Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.